SCHEMBL6367155

SCHEMBL6367155

O=C(Oc1cccc2c1C(=O)c1cccc(OC(=O)c3ccccc3)c1C2=O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.69
PTGES O14684 1/20 0.61
KMT2A Q03164 6/20 0.61
MAPT P10636 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
SLC6A3 Q01959 1/20 0.54
MEN1 O00255 2/20 0.53
USP2 O75604 2/20 0.53
HSD17B10 Q99714 2/20 0.53
ESR1 P03372 2/20 0.53
ESR2 Q92731 2/20 0.53
JAK2 O60674 1/20 0.53
GAA P10253 1/20 0.53
ALOX15 P16050 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TTR P02766 3/20 0.52
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
PARP1 P09874 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11524597 0.97 TOP1 (0.66) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL11525810 0.91 EGFR (0.60) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL11529372 0.89 EGFR (0.57) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL6367150 0.85 ESR1 (0.56) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL27584326 0.85 S100A4 (0.57) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL6366348 0.83 KMT2A (0.58) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL16473011 0.82 TOP1 (0.64) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL27584375 0.82 KMT2A (0.55) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL9680641 0.82 TOP1 (0.64) TOP1PTGESKMT2AMAPTSMN1; SMN2
SCHEMBL12827331 0.82 TOP1 (1.00) TOP1PTGESKMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives HUANG HSU-SHAN (TW) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009924-A1 Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives NFE2L2, NR2F2, TFAM TOP1 3100/4885PTGES 2969/4885KMT2A 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.